MarketCapExport financials
Integra LifeSciences Holdings Corporation (IART)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Integra LifeSciences Holdings Corporation IART
$ 15.53
2.76%
Facebook
X
Telegram
Integra LifeSciences Holdings Corporation Balance Sheet 2025-2007 | IART
Brief overview of Integra LifeSciences Holdings Corporation's balance sheet structure
The balance sheet is assessed across five available annual reports spanning 2020 to 2024.
Assets moved from $3.6 billion to $4 billion, a rise of +11.7%. CAGR near 2.8% indicates restrained expansion.
Asset and liability trends were close, at +11.7% and +18.7%. Expansion did not materially reshape funding sources.
Shareholders' equity accounts for 38.3% of assets, previously 41.9%. Dependence on liabilities is moderate.
Net debt is $528.6 million, or 0.34x of equity. This is a conservative debt position.
Cash represents 6.1% of assets versus 13% initially, showing how the immediate liquidity reserve changed.
By the end of the period, accumulated earnings were $939.9 million; the change from the start was +76.6%.
Balance sheet takeaway
Integra LifeSciences Holdings Corporation's balance sheet is broadly resilient, though selected areas require monitoring. The balance between assets, equity and liabilities remains the key issue.
Annual Balance Sheet Integra LifeSciences Holdings Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
506 M | 529 M | 514 M | 333 M | 65.8 M | 951 M | 1.15 B | 1.22 B | 1.67 B | 563 M | 667 M | 558 M | 271 M | 423 M | 431 M | 26.4 M | 76.9 M | - | - |
Long Term Debt |
727 M | 760 M | 775 M | 775 M | 564 M | 1.41 B | 1.3 B | 1.33 B | 1.78 B | 665 M | 701 M | 626 M | 392 M | 520 M | 532 M | 155 M | 149 M | - | - |
Long Term Debt Current |
14 M | 14.5 M | 15.3 M | 14.6 M | 14.8 M | 12.8 M | 12.3 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 1.56 B | 1.47 B | 1.9 B | 845 M | 884 M | 748 M | 407 M | 539 M | 550 M | - | - | - | - |
Total Current Liabilities |
456 M | 922 M | 307 M | 321 M | 340 M | 401 M | 331 M | 263 M | 349 M | 124 M | 139 M | 126 M | 119 M | 107 M | 102 M | 202 M | 157 M | - | - |
Total Liabilities |
2.56 B | 2.49 B | 2.19 B | 2.09 B | 2.1 B | 2.1 B | 1.89 B | 1.73 B | 2.25 B | 968 M | 1.02 B | 874 M | 526 M | 646 M | 651 M | 519 M | 495 M | - | - |
Deferred Revenue |
11.5 M | 10.5 M | 8.54 M | 7.25 M | 5.3 M | 5.28 M | 4.77 M | 3.76 M | 11.1 M | 6.81 M | 5.67 M | 5.18 M | 4.2 M | 3.5 M | 4.54 M | 4.44 M | 4.08 M | - | - |
Retained Earnings |
423 M | 940 M | 947 M | 879 M | 699 M | 532 M | 399 M | 348 M | 285 M | 220 M | 146 M | 315 M | 285 M | 302 M | 261 M | 233 M | 167 M | - | - |
Total Assets |
3.6 B | 4.04 B | 3.78 B | 3.89 B | 3.78 B | 3.62 B | 3.3 B | 3.11 B | 3.21 B | 1.81 B | 1.77 B | 1.58 B | 1.2 B | 1.16 B | 1.14 B | 1.02 B | 940 M | - | - |
Cash and Cash Equivalents |
235 M | 246 M | 276 M | 457 M | 513 M | 470 M | 199 M | 139 M | 175 M | 102 M | 48.1 M | 71.7 M | 121 M | 96.9 M | 101 M | 129 M | 71.9 M | 184 M | 57.3 M |
Book Value |
1.04 B | 1.55 B | 1.59 B | 1.8 B | 1.68 B | 1.51 B | 1.42 B | 1.38 B | 962 M | 840 M | 751 M | 704 M | 670 M | 518 M | 493 M | 500 M | 445 M | - | - |
Total Shareholders Equity |
1.04 B | 1.55 B | 1.59 B | 1.8 B | 1.68 B | 1.51 B | 1.42 B | 1.38 B | 962 M | 840 M | 751 M | 704 M | 666 M | 518 M | 493 M | 500 M | 445 M | 372 M | 288 M |
All numbers in USD currency
Quarterly Balance Sheet Integra LifeSciences Holdings Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
707 M | 717 M | 736 M | 746 M | 756 M | 765 M | 770 M | 775 M | 775 M | 775 M | 775 M | 567 M | 810 M | - | 832 M | 564 M | 855 M | 866 M | 878 M | 878 M | 878 M | 878 M | 878 M | 878 M | 889 M | 900 M | 900 M | 900 M | 900 M | 900 M | 1.18 B | - | - | - | - | - | 225 M | 223 M | 221 M | 218 M | 218 M | 218 M | 218 M | 213 M | 213 M | 213 M | 213 M | 205 M | 205 M | 205 M | 205 M | 198 M | 198 M | 198 M | 198 M | 353 M | 353 M | 353 M | 353 M | 154 M | 152 M |
Total Liabilities |
2.52 B | 2.54 B | 2.61 B | 2.63 B | 2.53 B | 2.54 B | 2.54 B | 2.48 B | 2.16 B | 2.09 B | 2.07 B | 2.09 B | 2.08 B | - | 2.06 B | 2.1 B | 2.14 B | 2.14 B | 2.21 B | 2.1 B | 2.1 B | 2.1 B | 2.1 B | 1.89 B | 1.89 B | 1.89 B | 1.89 B | 1.73 B | 1.73 B | 1.73 B | 1.73 B | 2.25 B | 2.25 B | 2.25 B | 2.25 B | 968 M | 968 M | 968 M | 968 M | 1.02 B | 1.02 B | 1.02 B | 1.02 B | 883 M | 883 M | 874 M | 874 M | 526 M | 526 M | 526 M | 526 M | 646 M | 646 M | 646 M | 646 M | 651 M | 656 M | 656 M | 656 M | 488 M | 481 M |
Deferred Revenue |
11.7 M | 11.6 M | 11.3 M | 11.1 M | 10.5 M | 9.99 M | 9.9 M | 7.84 M | 8.14 M | 8.28 M | 7.74 M | 7.25 M | 6.36 M | - | 5.34 M | 5.3 M | 5.39 M | 5.89 M | 5.4 M | 5.28 M | 5.28 M | 5.28 M | 5.28 M | 4.77 M | 4.77 M | 4.77 M | 4.77 M | 3.76 M | 3.76 M | 3.76 M | 3.76 M | 11.1 M | 7.67 M | 8.42 M | 8.09 M | 6.81 M | 6.81 M | 6.81 M | 6.81 M | 5.67 M | 5.67 M | 5.67 M | 5.67 M | 5.18 M | 5.18 M | 5.18 M | 5.18 M | 4.2 M | 4.2 M | 4.2 M | 4.2 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 4.54 M | 4.54 M | 4.54 M | 4.54 M | 4.33 M | 4 M |
Retained Earnings |
423 M | 419 M | 425 M | 431 M | 915 M | 920 M | 931 M | 944 M | 927 M | 908 M | 903 M | 879 M | 826 M | - | 731 M | 699 M | 653 M | 610 M | 575 M | 532 M | 532 M | 532 M | 532 M | 399 M | 399 M | 399 M | 399 M | 348 M | 348 M | 348 M | 348 M | 285 M | 285 M | 285 M | 285 M | 220 M | 220 M | 220 M | 220 M | 146 M | 146 M | 146 M | 146 M | 315 M | 315 M | 315 M | 315 M | 281 M | 281 M | 281 M | 281 M | 302 M | 302 M | 302 M | 302 M | 261 M | 261 M | 261 M | 261 M | 214 M | 198 M |
Total Assets |
3.56 B | 3.58 B | 3.65 B | 3.67 B | 4.05 B | 4.07 B | 4.07 B | 4.08 B | 3.74 B | 3.78 B | 3.74 B | 3.89 B | 3.81 B | - | 3.67 B | 3.78 B | 3.77 B | 3.71 B | 3.74 B | 3.62 B | 3.62 B | 3.62 B | 3.62 B | 3.3 B | 3.3 B | 3.3 B | 3.3 B | 3.11 B | 3.11 B | 3.11 B | 3.11 B | 3.21 B | 3.21 B | 3.21 B | 3.21 B | 1.81 B | 1.81 B | 1.81 B | 1.81 B | 1.77 B | 1.77 B | 1.77 B | 1.77 B | 1.59 B | 1.59 B | 1.58 B | 1.58 B | 1.19 B | 1.19 B | 1.19 B | 1.19 B | 1.16 B | 1.16 B | 1.16 B | 1.16 B | 1.14 B | 1.15 B | 1.15 B | 1.15 B | 959 M | 942 M |
Cash and Cash Equivalents |
214 M | 237 M | 232 M | 218 M | 239 M | 215 M | 215 M | 592 M | 274 M | 309 M | 307 M | 457 M | 512 M | 447 M | 407 M | 513 M | 470 M | 397 M | 409 M | 470 M | 470 M | 470 M | 470 M | 199 M | 199 M | 199 M | 199 M | 139 M | 139 M | 139 M | 139 M | 175 M | 175 M | 175 M | 175 M | 102 M | 102 M | 102 M | 102 M | 48.1 M | 48.1 M | 48.1 M | 48.1 M | 71.7 M | 71.7 M | 72 M | 72 M | 121 M | 121 M | 121 M | 121 M | 96.9 M | 96.9 M | 96.9 M | 96.9 M | 101 M | 101 M | 101 M | 101 M | 82.8 M | 93.6 M |
Book Value |
1.04 B | 1.04 B | 1.04 B | 1.04 B | 1.52 B | 1.52 B | 1.53 B | 1.6 B | 1.58 B | 1.68 B | 1.67 B | 1.8 B | 1.72 B | - | 1.62 B | 1.68 B | 1.63 B | 1.57 B | 1.53 B | 1.51 B | 1.51 B | 1.51 B | 1.51 B | 1.42 B | 1.42 B | 1.42 B | 1.42 B | 1.38 B | 1.38 B | 1.38 B | 1.38 B | 962 M | 962 M | 962 M | 962 M | 840 M | 840 M | 840 M | 840 M | 751 M | 751 M | 751 M | 751 M | 704 M | 704 M | 704 M | 704 M | 666 M | 666 M | 666 M | 666 M | 518 M | 518 M | 518 M | 518 M | 493 M | 493 M | 493 M | 493 M | 471 M | 460 M |
Total Shareholders Equity |
1.04 B | 1.04 B | 1.04 B | 1.04 B | 1.52 B | 1.52 B | 1.53 B | 1.6 B | 1.58 B | 1.68 B | 1.67 B | 1.8 B | 1.72 B | 1.66 B | 1.62 B | 1.68 B | 1.63 B | 1.57 B | 1.53 B | 1.51 B | 1.51 B | 1.51 B | 1.51 B | 1.42 B | 1.42 B | 1.42 B | 1.42 B | 1.38 B | 1.38 B | 1.38 B | 1.38 B | 962 M | 962 M | 962 M | 962 M | 840 M | 840 M | 840 M | 840 M | 751 M | 751 M | 751 M | 751 M | 704 M | 704 M | 704 M | 704 M | 666 M | 666 M | 666 M | 666 M | 518 M | 518 M | 518 M | 518 M | 493 M | 493 M | 493 M | 493 M | 471 M | 460 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Integra LifeSciences Holdings Corporation, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Medical devices
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
AxoGen
AXGN
|
$ 43.32 | 0.04 % | $ 1.99 B |  USA |
 |
Bruker Corporation
BRKR
|
$ 59.67 | 0.18 % | $ 9.06 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
$ 8.73 | 1.16 % | $ 637 M |  Israel |
 |
ClearPoint Neuro
CLPT
|
$ 14.97 | 13.03 % | $ 424 M | USA |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
CONMED Corporation
CNMD
|
$ 45.8 | 3.31 % | $ 1.42 B | USA |
 |
Cytosorbents Corporation
CTSO
|
$ 4.91 | 0.75 % | $ 306 M | USA |
 |
Delcath Systems
DCTH
|
$ 15.96 | 1.8 % | $ 572 M | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
AdaptHealth Corp.
AHCO
|
$ 5.7 | 0.43 % | $ 770 M | USA |
 |
Electromed
ELMD
|
$ 27.57 | 0.11 % | $ 228 M | USA |
 |
Establishment Labs Holdings
ESTA
|
$ 67.76 | 3.69 % | $ 2.01 B |  Costa-rica |
 |
Edwards Lifesciences Corporation
EW
|
$ 86.82 | 0.51 % | $ 50.8 B | USA |
 |
Align Technology
ALGN
|
$ 148.17 | 4.36 % | $ 10.7 B | USA |
 |
Helius Medical Technologies
HSDT
|
$ 2.88 | 2.45 % | $ 63.5 M | USA |
 |
Inogen
INGN
|
$ 5.09 | 2.55 % | $ 135 M | USA |
 |
Inspire Medical Systems
INSP
|
$ 69.06 | 0.57 % | $ 2.03 B | USA |
 |
IRIDEX Corporation
IRIX
|
$ 0.63 | 0.08 % | $ 10.7 M | USA |
 |
IRadimed Corporation
IRMD
|
$ 86.35 | 0.08 % | $ 1.1 B | USA |
 |
Integer Holdings Corporation
ITGR
|
$ 126.32 | 0.02 % | $ 4.39 B | USA |
|
LENSAR
LNSR
|
$ 7.15 | 0.14 % | $ 85.5 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Apyx Medical Corporation
APYX
|
$ 2.95 | 1.37 % | $ 121 M | USA |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Medtronic PLC
MDT
|
$ 89.3 | 0.08 % | $ 114 B | USA |
 |
MiMedx Group
MDXG
|
$ 4.77 | 0.2 % | $ 705 M | USA |
 |
Accuray Incorporated
ARAY
|
$ 0.23 | 1.0 % | $ 28.2 M | USA |
 |
Myomo
MYO
|
$ 1.64 | 0.3 % | $ 68.6 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.7 | 0.45 % | $ 45.4 M | Israel |
 |
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M |  Britain |
 |
InspireMD
NSPR
|
$ 0.74 | 0.16 % | $ 47.6 M | Israel |
 |
Orthofix Medical
OFIX
|
$ 9.18 | 2.23 % | $ 364 M |  Curacao |
 |
Outset Medical
OM
|
$ 3.09 | 5.45 % | $ 47 K | USA |
 |
Boston Scientific Corporation
BSX
|
$ 44.62 | 0.31 % | $ 66.1 B | USA |
 |
Insulet Corporation
PODD
|
$ 136.49 | 0.01 % | $ 9.6 B | USA |
 |
Profound Medical Corp.
PROF
|
$ 5.74 | 0.16 % | $ 174 M |  Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.16 | 4.93 % | $ 135 M | USA |
 |
AVITA Medical
RCEL
|
$ 10.95 | 0.61 % | $ 305 M |  Australia |
 |
Neovasc
NVCN
|
- | - | $ 111 M | Canada |
 |
Sintx Technologies
SINT
|
$ 1.78 | 3.98 % | $ 4.94 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 26.82 | 0.07 % | $ 23.3 B | Britain |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |
 |
Sensus Healthcare
SRTS
|
$ 3.03 | 0.32 % | $ 49.5 M | USA |
 |
Stryker Corporation
SYK
|
$ 273.4 | 0.38 % | $ 104 B | USA |
 |
Tactile Systems Technology
TCMD
|
$ 22.43 | 0.55 % | $ 513 M | USA |
 |
TELA Bio
TELA
|
$ 1.3 | 0.71 % | $ 61 M | USA |
 |
Viemed Healthcare
VMD
|
$ 8.8 | 1.24 % | $ 342 M | USA |
 |
Varex Imaging Corporation
VREX
|
$ 18.45 | 0.05 % | $ 764 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |